Kimberly Warren to Humans
This is a "connection" page, showing publications Kimberly Warren has written about Humans.
Connection Strength
0.148
-
Warren KR, Wehring HJ, Liu F, McMahon RP, Chen S, Chester C, Kelly DL. Effects of intranasal oxytocin on satiety signaling in people with schizophrenia. Physiol Behav. 2018 05 15; 189:86-91.
Score: 0.031
-
Warren KR, Postolache TT, Groer ME, Pinjari O, Kelly DL, Reynolds MA. Role of chronic stress and depression in periodontal diseases. Periodontol 2000. 2014 Feb; 64(1):127-38.
Score: 0.023
-
Warren KR, Buchanan RW, Feldman S, Conley RR, Linthicum J, Ball MP, Liu F, McMahon RP, Gorelick DA, Huestis MA, Kelly DL. Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol. 2013 Feb; 33(1):118-20.
Score: 0.022
-
Warren KR, Ball MP, Feldman S, Liu F, McMahon RP, Kelly DL. Exercise program adherence using a 5-kilometer (5K) event as an achievable goal in people with schizophrenia. Biol Res Nurs. 2011 Oct; 13(4):383-90.
Score: 0.019
-
Elkashef A, Bra?ic JR, Cantelina LR, Kahn R, Chiang N, Ye W, Zhou Y, Mojsiak J, Warren KR, Crabb A, Hilton J, Wong DF, Vocci F. A cholecystokinin B receptor antagonist and cocaine interaction, phase I study. CNS Neurosci Ther. 2019 01; 25(1):136-146.
Score: 0.008
-
Koola MM, Gorelick DA, McMahon RP, Liu F, Huestis MA, Linthicum J, Feldman SM, Warren KR, Wehring HJ, Kelly DL. Psychiatric symptom differences in people with schizophrenia associated with substantial lifetime substance use but no current substance use disorder. Schizophr Res. 2014 Jan; 152(1):315-6.
Score: 0.006
-
Jackson J, Eaton W, Cascella N, Fasano A, Warfel D, Feldman S, Richardson C, Vyas G, Linthicum J, Santora D, Warren KR, Carpenter WT, Kelly DL. A gluten-free diet in people with schizophrenia and anti-tissue transglutaminase or anti-gliadin antibodies. Schizophr Res. 2012 Sep; 140(1-3):262-3.
Score: 0.005
-
Koola MM, McMahon RP, Wehring HJ, Liu F, Mackowick KM, Warren KR, Feldman S, Shim JC, Love RC, Kelly DL. Alcohol and cannabis use and mortality in people with schizophrenia and related psychotic disorders. J Psychiatr Res. 2012 Aug; 46(8):987-93.
Score: 0.005
-
Ball MP, Warren KR, Feldman S, McMahon RP, Kelly DL, Buchanan RW. Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. Clin Schizophr Relat Psychoses. 2011 Apr; 5(1):17-25.
Score: 0.005
-
Strauss GP, Wilbur RC, Warren KR, August SM, Gold JM. Anticipatory vs. consummatory pleasure: what is the nature of hedonic deficits in schizophrenia? Psychiatry Res. 2011 May 15; 187(1-2):36-41.
Score: 0.005
-
Kelly DL, Gorelick DA, Conley RR, Boggs DL, Linthicum J, Liu F, Feldman S, Ball MP, Wehring HJ, McMahon RP, Huestis MA, Heishman SJ, Warren KR, Buchanan RW. Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol. 2011 Feb; 31(1):86-91.
Score: 0.005
-
Wehring HJ, Liu F, McMahon RP, Spieker EA, Warren KR, Boggs DL, Love RC, Dickinson D, Shim JC, Fowler D, Kelly DL. The relationship of brain weight to body mass index (BMI) upon autopsy in young people with severe mental illness. Schizophr Res. 2010 Oct; 123(1):86-7.
Score: 0.005
-
Kelly DL, McMahon RP, Liu F, Love RC, Wehring HJ, Shim JC, Warren KR, Conley RR. Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J Clin Psychiatry. 2010 Mar; 71(3):304-11.
Score: 0.004
-
Kelly DL, McMahon RP, Wehring HJ, Liu F, Mackowick KM, Boggs DL, Warren KR, Feldman S, Shim JC, Love RC, Dixon L. Cigarette smoking and mortality risk in people with schizophrenia. Schizophr Bull. 2011 Jul; 37(4):832-8.
Score: 0.004